Patients with varying stages of glaucoma saw no significant difference in outcomes between standard and enhanced monofocal ...

Goniotomy may be a first-line approach to treating pediatric patients with glaucoma secondary to uveitis, with improvements ...

ALPHARETTA, Ga. - Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company with a market capitalization of $85.7 million focused on developing therapies for ocular diseases, has announced ...

Patient age in uveitis diagnoses and treatment plays a significant role, according to research published in American Journal of Ophthalmology.

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

Treatment Landscape The treatment of uveitis has evolved significantly, with a focus on reducing inflammation, managing symptoms, and preventing complications. Key treatment options include ...

I turned 50 during the pandemic and, like most people, I put off all nonessential health care, including my shingles vaccine. Big mistake. When the telltale red bumps of shingles cropped up on my ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...

Background: Adalimumab taken every other week is an effective treatment in patients with chronic refractory uveitis. Patients who have a suboptimal response to this treatment may suffer from recurrent ...

Infliximab is more effective and safer than etanercept in the treatment of patients with noninfectious uveitis. Adalimumab is valid for severe uveitis, reducing efficacy for treatment of infliximab.